Present theranostic agents, such as 177Lu-based compounds targeting somatostatin receptor and prostate-specific membranous antigen (PSMA) expressing metastatic disease, are mostly metabolized in the kidneys [28, 29]. The gene discussed is FOLH1; the disease is metastatic neoplasm.